

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**三生制药**  
**3SBIO INC.**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1530)**

**VOLUNTARY ANNOUNCEMENT  
FIRST PATIENT ENROLLED IN  
THE TRIAL OF PHASE III CLINICAL STUDY OF  
3SBIO'S RECOMBINANT HUMAN THROMBOPOIETIN (rhTPO)  
INJECTION (TPIAO®) IN THE TREATMENT OF  
CHRONIC LIVER DISEASE RELATED THROMBOCYTOPENIA**

3SBio Inc. (the “**Company**”) wishes to provide to the shareholders of the Company the attached press release in respect of the first patient being recently enrolled in the trial of Phase III clinical study of recombinant human thrombopoietin (rhTPO) injection (trade name: TPIAO®) in the treatment of patients with chronic liver disease related thrombocytopenia who are candidates for invasive surgery (project number: TPO106).

This is a voluntary announcement made by the Company. The Company cannot guarantee that it is able to successfully develop or eventually launch and/or commercialize such product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**3SBio Inc.**  
**Dr. LOU Jing**  
*Chairman*

Shenyang, the PRC  
22 May 2023

*As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin as non-executive Directors; and Mr. PU Tianruo, Ms. YANG, Hoi Ti Heidi, Mr. NG, Joo Yeow Gerry and Dr. Zhang Dan as independent non-executive Directors.*

# **FIRST PATIENT ENROLLED IN THE TRIAL OF PHASE III CLINICAL STUDY OF 3SBIO'S RECOMBINANT HUMAN THROMBOPOIETIN (rhTPO) INJECTION (TPIAO®) IN THE TREATMENT OF CHRONIC LIVER DISEASE RELATED THROMBOCYTOPENIA**

3SBio Inc. (01530.HK) announces today that the first patient has recently been enrolled in the trial of Phase III clinical study of recombinant human thrombopoietin (rhTPO) injection (trade name: TPIAO®) in the treatment of patients with chronic liver disease related thrombocytopenia who are candidates for invasive surgery (project number: TPO106).

TPIAO® is a recombinant human thrombopoietin (rhTPO) injection developed by 3SBio, which has been approved for treatment of chemotherapy-induced thrombocytopenia (CIT) with solid tumors and immune thrombocytopenia (ITP) indications in adult patients. In 2022, the marketing application of TPIAO® in pediatric ITP indication was accepted by the National Medical Products Administration (NMPA) of China. In the field of chronic liver disease, TPIAO® is also actively expanding its indications, and exploratory studies on safety, tolerability, pharmacokinetics (PK) and preliminary efficacy have been conducted on patients with chronic liver disease complicated with thrombocytopenia. Thrombocytopenia is a common complication of chronic liver disease, the degree of which is related to the severity of liver disease. About 78% of patients with liver cirrhosis have varying degrees of thrombocytopenia. The main cause of thrombocytopenia in patients with chronic liver disease is decreased production of thrombopoietin (TPO). Other factors include hypersplenism, increased platelet destruction, and bone marrow suppression by virus. For patients with chronic liver disease requiring surgery treatment, thrombocytopenia can lead to increased risk of surgery-related bleeding. At present, platelet transfusion is the main treatment to reduce the risk of surgical bleeding. However, its source is scarce and the curative effect is short-lived. It also carries risks of blood transfusion reaction and potential transfusion infection, limiting its application. Patients with chronic liver disease complicated with thrombocytopenia urgently need more effective and safe alternative treatment methods.

“TPIAO® has been proven in long-term clinical practice to be a drug worthy of trust by doctors and patients, and we believe that it will continue to perform well in the treatment of patients with chronic liver diseases. Thrombocytopenia is related to many diseases and affects the relevant treatment process. The Company will continue its efforts to expand the indications of TPIAO®, explore the potential of the drug, and strive to benefit patients in more clinical fields.” said Dr. LOU Jing, Chairman of 3SBio.

## **About 3SBio Inc.**

3SBio Inc. is a leading biopharmaceutical company integrating research and development (“R&D”), production and sales, with a focus on improving the life quality of patients with high quality medicines to benefit human health. At present, the Company owns more than 100 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, including, among others, nephrology, oncology, autoimmune, ophthalmology and dermatology. The Company owns four R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 31 kinds of products under R&D, 26 kinds of which are national new drugs. The Group also owns five production bases complying with the GMP standards. In the future, 3SBio Inc. will continue to uphold the concept of “Care for Life, Cherish Life, Create Life” to create a world-leading biopharmaceutical company in China. Please visit [www.3sbio.com](http://www.3sbio.com) for additional information.

## **Cautionary Note and Forward-Looking Statements**

This press release contains forward-looking statements, such as those relating to business or products outlook, or the Company’s intent, plans, beliefs, expectation and strategies. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond our control. These forward-looking statements may prove to be incorrect or may not be realized in the future. With respect to any new product or new indication, we cannot guarantee that we will be able to successfully develop or eventually launch and market such product or indication. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding such risks and uncertainties may be found in our other public disclosure documents. The scientific information involved may only be preliminary and empirical. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.